MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
TSX:DR - CA58457V5036 - Common Stock
14.35 CAD
-0.19 (-1.31%)
DR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 15 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making DR a very profitable company, without any liquidiy or solvency issues. DR has a bad growth rate and is valued cheaply. With these ratings, DR could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year DR was profitable.
DR had a positive operating cash flow in the past year.
Of the past 5 years DR 4 years were profitable.
DR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DR has a Return On Assets of 29.34%. This is amongst the best in the industry. DR outperforms 93.33% of its industry peers.
Looking at the Return On Equity, with a value of 105.57%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DR's Return On Invested Capital of 16.22% is amongst the best of the industry. DR outperforms 93.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DR is significantly above the industry average of 7.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROIC | 16.22% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
The Profit Margin of DR (28.90%) is better than 93.33% of its industry peers.
DR's Profit Margin has improved in the last couple of years.
The Operating Margin of DR (14.93%) is better than 100.00% of its industry peers.
DR's Operating Margin has been stable in the last couple of years.
The Gross Margin of DR (65.05%) is better than 93.33% of its industry peers.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
The number of shares outstanding for DR has been reduced compared to 1 year ago.
Compared to 5 years ago, DR has less shares outstanding
The debt/assets ratio for DR has been reduced compared to a year ago.
2.2 Solvency
DR has an Altman-Z score of 1.29. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DR (1.29) is comparable to the rest of the industry.
DR has a debt to FCF ratio of 1.88. This is a very positive value and a sign of high solvency as it would only need 1.88 years to pay back of all of its debts.
The Debt to FCF ratio of DR (1.88) is better than 93.33% of its industry peers.
A Debt/Equity ratio of 1.25 is on the high side and indicates that DR has dependencies on debt financing.
DR has a Debt to Equity ratio (1.25) which is in line with its industry peers.
Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Altman-Z | 1.29 |
ROIC/WACC1.98
WACC8.21%
2.3 Liquidity
A Current Ratio of 1.58 indicates that DR should not have too much problems paying its short term obligations.
With an excellent Current ratio value of 1.58, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DR has a Quick Ratio of 1.48. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of DR (1.48) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 |
3. Growth
3.1 Past
DR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 193.02%, which is quite impressive.
The Revenue for DR has decreased by -37.06% in the past year. This is quite bad
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
3.2 Future
Based on estimates for the next years, DR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.76% on average per year.
The Revenue is expected to decrease by -7.10% on average over the next years.
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.25, the valuation of DR can be described as very reasonable.
93.33% of the companies in the same industry are more expensive than DR, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.08, DR is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 9.15, the valuation of DR can be described as reasonable.
Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.67. DR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.25 | ||
| Fwd PE | 9.15 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DR indicates a rather cheap valuation: DR is cheaper than 100.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, DR is valued cheaper than 93.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.36 | ||
| EV/EBITDA | 4.25 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y9.79%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
DR has a Yearly Dividend Yield of 2.47%. Purely for dividend investing, there may be better candidates out there.
DR's Dividend Yield is a higher than the industry average which is at 3.34.
Compared to an average S&P500 Dividend Yield of 2.34, DR has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has paid a dividend for at least 10 years, which is a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
DR pays out 7.21% of its income as dividend. This is a sustainable payout ratio.
DP7.21%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
TSX:DR (8/26/2025, 7:00:00 PM)
14.35
-0.19 (-1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners12.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap268.06M
Analysts42.22
Price Target16.58 (15.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
Yearly Dividend0.36
Dividend Growth(5Y)-19.91%
DP7.21%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.26%
Min EPS beat(2)-24.98%
Max EPS beat(2)-7.54%
EPS beat(4)1
Avg EPS beat(4)-8.64%
Min EPS beat(4)-41.75%
Max EPS beat(4)39.71%
EPS beat(8)2
Avg EPS beat(8)-39.68%
EPS beat(12)4
Avg EPS beat(12)4.47%
EPS beat(16)6
Avg EPS beat(16)-104.58%
Revenue beat(2)0
Avg Revenue beat(2)-4.32%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)-4.13%
Revenue beat(4)0
Avg Revenue beat(4)-8.01%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)-4.13%
Revenue beat(8)2
Avg Revenue beat(8)-4.04%
Revenue beat(12)3
Avg Revenue beat(12)-2.78%
Revenue beat(16)4
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)50.31%
EPS NY rev (3m)50.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.25 | ||
| Fwd PE | 9.15 | ||
| P/S | 0.7 | ||
| P/FCF | 3.36 | ||
| P/OCF | 3.17 | ||
| P/B | 2.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.25 |
EPS(TTM)1.74
EY12.13%
EPS(NY)1.57
Fwd EY10.93%
FCF(TTM)4.27
FCFY29.74%
OCF(TTM)4.53
OCFY31.59%
SpS20.63
BVpS5.65
TBVpS-1.58
PEG (NY)0.25
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROCE | 19.63% | ||
| ROIC | 16.22% | ||
| ROICexc | 21.11% | ||
| ROICexgc | 52.76% | ||
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% | ||
| FCFM | 20.69% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexcg growth 3Y35.06%
ROICexcg growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Debt/EBITDA | 1.6 | ||
| Cap/Depr | 20.05% | ||
| Cap/Sales | 1.29% | ||
| Interest Coverage | 6.5 | ||
| Cash Conversion | 102.93% | ||
| Profit Quality | 71.58% | ||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | 1.29 |
F-Score6
WACC8.21%
ROIC/WACC1.98
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-43.39%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year-3.9%
EBIT Next 3Y2%
EBIT Next 5YN/A
FCF growth 1Y-0.32%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-10.39%
OCF growth 3Y3.26%
OCF growth 5Y1.55%